Revolution Medicines Confident in RAS Leadership as Rivals Square Up: Recent News Summary (June 2026) on June 03, 2026 Actuate Therapeutics Alan Sandler ASCO confident daraxonrasib Erasca Leadership Pancreatic carcinoma RAS RAS inhibitors ras Oncogene RevMed Revolution Medicines rivals square +
Revolution Medicines Rejects Merck's Acquisition Bid, Stands Firm on Valuation Amid Ongoing Interest on January 26, 2026 acquisition talks daraxonrasib M&A Merck RAS RAS inhibitors Revolution Medicines +